Could a papaya supplement help aging skin hold onto moisture?

NCT ID NCT07725835

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This pilot study tests whether a daily fermented papaya supplement can improve skin barrier function in healthy adults aged 50 to 75. The main focus is on reducing water loss from the skin on the face, arms, and hands, measured with a non-invasive device. Participants take the supplement for 12 weeks and attend five visits over 20 weeks, including blood draws to check inflammation and blood sugar markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a fermented papaya dietary supplement called Immun'Age
What this could lead to
If it works, this could point toward a simple dietary supplement to support skin barrier health in aging skin.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply broadly. The supplement may have no measurable effect on skin hydration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 50-75 years 2. Willing to allow collection of 3 blood samples (Baseline, Week 12 and Week 20) 3. Willing to log daily compliance with FPP intake during the study period (12 weeks) 4. Absence of active systemic disease per investigator judgement. 5. No current use of immunosuppressant or immunomodulatory medications. 6. No active dermatological conditions at measurement sites that could impair measure, per investigator judgement. 7. Investigator determination of general good health. Exclusion Criteria: 1. Co-morbidity or concurrent medication that the Investigator deems impactful to patient safety or ability to adhere to FPP dosage. 2. Co-morbidity or concurrent medication that the Investigator deems confounding to outcome measure (i.e., topical or systemic steroid). 3. Current or history of allergy to FPP ingredients: Dextrose, Carica papaya, or Food yeast. 4. Concurrent participation in another interventional trial that may impact measures, per investigator judgement. 5. Uncontrolled diabetes (A1c \>7%). 6. Open wounds or actively receiving Wound Care services. 7. Pregnant or breastfeeding women. 8. Current use of warfarin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • McGowan Institute for Regenerative Medicine

    Pittsburgh, Pennsylvania, 15219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.